Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$853,488
+$357,949 QoQ
Shares Held
34,085
-18.1% QoQ
Ownership
0.047%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HighVista Strategies LLC holds $224,607,258 across 76 Biotechnology names. ZYME ranks #65 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
113,254 | $12,610,832 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
26,323 | $8,481,007 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
197,051 | $7,584,492 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
146,264 | $7,377,556 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
124,647 | $7,243,237 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
69,309 | $6,740,300 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
114,307 | $6,026,265 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
123,909 | $5,972,413 |
All Filings in ZYME
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $853,488 | 34,085 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $495,539 | 41,607 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||